The ₹440 crore IPO of Amir Chand Jagdish Kumar (Exports) launched today, March 24, 2026, with a price band of ₹201–₹212. A 100% fresh issue, the company is leveraging its iconic "Aeroplane" brand to fuel a massive working capital push. We look at the 29% revenue growth, the current ₹6 GMP, and whether this "Three Star Export House" fits your portfolio.
The ₹21.67 crore IPO of Highness Microelectronics launched today, March 24, 2026, with a price band of ₹114–₹120. Operating in the specialized "rugged display" market for medical and defense sectors, the company is looking to fund a new assembly line in Mumbai. With a current GMP of ₹10 (8% gain), we analyze if this SME issue is a "buy" for your portfolio.
Hyderabad-based Sai Parenteral's Limited launched its ₹409 crore IPO today, March 24, 2026, with a price band of ₹372–₹392. With a bold move to acquire Australia’s Noumed Pharmaceuticals, the company is shifting from a domestic manufacturer to a global CDMO powerhouse. We analyze the 72x P/E valuation, the flat GMP, and the long-term potential of this injectable specialist.
Industrial machinery specialist Tipco Engineering India is in the middle of its ₹61 crore SME IPO, open until March 25, 2026. With a massive 3-year revenue CAGR of 92% and a P/E ratio under 9x, the company looks undervalued compared to its peers. We break down the Day 2 subscription, the flat GMP, and why the "Debt Repayment" objective is a game-changer.
Mumbai-based Speciality Medicines Limited wraps up its ₹29.14 crore SME IPO today, March 24, 2026. With a portfolio of 900+ products and a massive 3x jump in profit last year, the company is looking to build its own R&D center. We dive into the current 1x subscription status, the flat GMP, and the long-term outlook for this specialty pharma distributor.
The ₹1,842 crore IPO of Central Mine Planning & Design Institute (CMPDI), a critical technical arm of Coal India, closes for subscription today, March 24, 2026. Priced at ₹163–₹172, this 100% Offer for Sale (OFS) is a value-play for those eyeing India’s core energy sector. We look at the 25% Day 2 subscription, the ₹1.50 GMP, and why long-term investors are watching this one.
Navi Mumbai-based Vivid Electromech launches its ₹130.54 crore SME IPO on March 25, 2026. With 30+ years of experience and a massive 74% revenue growth last year, the company is targeting the rapidly expanding data center and metro rail sectors. We dive into the ₹528–₹555 price band, the flat GMP, and the ambitious 3x capacity expansion plan.
SME engineering firm Tipco Engineering hits the primary market today, March 23, 2026, with a price band of ₹84–₹89. Despite a flat early Grey Market Premium (GMP), the company’s 4x revenue growth over the last two years and its plans to become debt-free make it a notable entry in the industrial equipment space.
Mumbai-based Speciality Medicines Limited is currently live with its ₹29.14 crore SME IPO. Priced at ₹117–₹124, this 100% fresh issue is a strategic play to pivot from distribution to in-house R&D. With Day 2 bidding underway and a listing scheduled for March 30, we break down the subscription trends, the ₹0 GMP, and the long-term potential.
The ₹1,842 crore IPO of Coal India’s consultancy arm, CMPDI, is seeing a measured response on its second day of bidding. As of midday March 23, 2026, the issue is subscribed 0.09x, with retail and existing Coal India shareholders showing the most movement. With a Grey Market Premium (GMP) of ₹1.5, the market is pricing this as a long-term "Value PSU" play rather than a quick listing-gain firework.
Electrical switchboard manufacturer Vivid Electromech Ltd is set to launch its IPO on March 25, 2026, with a price band of ₹528–₹555. Boasting a massive revenue jump to ₹155 crore and a 30-year industry legacy, the company is eyeing expansion into new manufacturing units. We break down the financials, the ₹2.66 lakh entry barrier, and what to expect.
Hyderabad-based Sai Parenteral's Limited enters the mainboard market on March 24, 2026, with a price band of ₹372–₹392. Specializing in sterile injectables and high-end formulations, the company is using this IPO to fund a major Australian acquisition and a new R&D center. We break down the ₹0 GMP, the 72x valuation, and the risks you should know.
GMP IPO Watch
Open IPO
